The U.S. Food and Drug Administration said it will immediately require boxed warnings about the risk of serious neuropsychiatric symptoms on the packaging of two popular alleged smoking cessation drugs –  varenicline (Chantix, Champix) and buproprion (Zyban, Wellbutrin and generics).

Reports of behavioral changes, depression, agitation, hostility and suicidal thoughts and behavior associated with use of the drugs have been submitted to the FDA’s adverse event reporting system.

Throughout the marketing history of the drugs, there have been 98 suicides and 188 attempted suicides in varenicline (Chantix / Champix) users and 14 suicides and 17 attempted suicides in buproprion (Zyban, Wellbutrin) users, the agency reported.

Please click here for more information about the Chantix controversy.

Source